ZA200802947B - Stable pharmaceutical composition comprising a pyrimidine-sulfamide - Google Patents

Stable pharmaceutical composition comprising a pyrimidine-sulfamide

Info

Publication number: ZA200802947B
Authority: ZA; South Africa
Prior art keywords: sulfamide; pyrimidine; pharmaceutical composition; stable pharmaceutical; stable
Prior art date: 2005-09-12

Application number

ZA200802947A

Other languages

English (en)

Inventor

Charles Tokunbo Adesuyi

Lovelace Holman

Olivier Lambert

Bruce Hamiton Lithgow

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-12

Filing date

2008-04-03

Publication date

2009-12-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200802947(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-03 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2009-12-30 Publication of ZA200802947B publication Critical patent/ZA200802947B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200802947A 2005-09-12 2008-04-03 Stable pharmaceutical composition comprising a pyrimidine-sulfamide ZA200802947B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP2005009775		2005-09-12

Publications (1)

Publication Number	Publication Date
ZA200802947B true ZA200802947B (en)	2009-12-30

Family

ID=37865339

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200802947A ZA200802947B (en)	2005-09-12	2008-04-03	Stable pharmaceutical composition comprising a pyrimidine-sulfamide

Country Status (24)

Country	Link
US (6)	US20080233188A1 (pt)
EP (2)	EP1928409B1 (pt)
JP (2)	JP4955685B2 (pt)
KR (1)	KR101313395B1 (pt)
CN (1)	CN101262847B (pt)
AU (1)	AU2006290309B2 (pt)
BR (1)	BRPI0615898B8 (pt)
CA (1)	CA2621273C (pt)
CY (1)	CY1113395T1 (pt)
DK (1)	DK1928409T3 (pt)
ES (1)	ES2393117T3 (pt)
HK (1)	HK1121950A1 (pt)
HR (1)	HRP20120957T1 (pt)
IL (1)	IL190072A (pt)
MY (1)	MY151003A (pt)
NO (1)	NO341325B1 (pt)
NZ (1)	NZ567188A (pt)
PL (1)	PL1928409T3 (pt)
PT (1)	PT1928409E (pt)
RU (1)	RU2424805C2 (pt)
SI (1)	SI1928409T1 (pt)
TW (1)	TWI323661B (pt)
WO (1)	WO2007031933A2 (pt)
ZA (1)	ZA200802947B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1928409E (pt)	2005-09-12	2012-11-27	Actelion Pharmaceuticals Ltd	Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) *	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
TWI399223B (zh) *	2006-09-15	2013-06-21	Daiichi Sankyo Co Ltd	奧美沙坦酯及氨氯地平之固體劑型
MX2010001837A (es) *	2007-08-17	2010-03-10	Actelion Pharmaceuticals Ltd	Derivados de 4-pirimidinasulfamida.
WO2009104149A1 (en) *	2008-02-20	2009-08-27	Actelion Pharmaceuticals Ltd	Combination comprising paclitaxel for treating ovarian cancer
PT2315587T (pt) *	2008-08-13	2018-01-31	Actelion Pharmaceuticals Ltd	Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
DK2464218T3 (en)	2009-08-10	2015-07-20	Univ Texas	Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic agent for chemotherapy
DK2512455T3 (en)	2009-12-18	2014-03-24	Frieslandcampina Nederland Holding B V	Co-treated tablet adjuvant composition, its preparation and use
IT1403248B1 (it) *	2010-11-12	2013-10-17	Scharper Therapeutics Srl	Composizione per il trattamento di disfunzioni degli apparati fonatorio ed olfattorio
BR112013019680A2 (pt)	2011-02-04	2016-10-11	Actelion Pharmaceuticals Ltd	combinações compreendendo macitentana para o tratamento de glioblastoma multiforme
DE14721256T1 (de) *	2013-04-22	2017-03-16	Sandoz Ag	Pharmazeutische zusammensetzungen mit kristallinem macitentan
SG11201509998WA (en)	2013-06-13	2016-01-28	Akebia Therapeutics Inc	Compositions and methods for treating anemia
WO2014198178A1 (zh) *	2013-06-14	2014-12-18	杭州普晒医药科技有限公司	马西替坦晶体及其制备方法、其药物组合物和用途
WO2016009322A1 (en) *	2014-07-15	2016-01-21	Sifavitor S.R.L.	Amorphous form and new crystalline forms of macitentan
CN106714784A (zh)	2014-07-25	2017-05-24	诺华股份有限公司	2‑氟‑N‑甲基‑4‑[7‑(喹啉‑6‑基甲基)咪唑并[1,2‑b][1,2,4]三嗪‑2‑基]苯甲酰胺的片剂制剂
CN105388244B (zh) *	2015-12-10	2017-03-08	合肥久诺医药科技有限公司	一种马西替坦有关物质的高效液相色谱分析方法
WO2018153925A1 (en)	2017-02-22	2018-08-30	Amneal Pharmaceuticals Company Gmbh	Stable pharmaceutical compositions comprising macitentan
CA3123990A1 (en) *	2018-12-21	2020-06-25	Actelion Pharmaceuticals Ltd	Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) *	2019-01-25	2020-12-01	瑞士商艾克泰聯製藥有限公司	用於治療慢性血栓性肺高血壓之醫藥組成物
DK3993777T3 (da) *	2019-07-05	2024-09-16	Tecnimede Sociedade Tecnico Medicinal Sa	Komprimerede macitentansammensætninger, fremgangsmåder og anvendelser deraf
AU2020392424A1 (en)	2019-11-29	2022-06-02	Actelion Pharmaceuticals Ltd	Methods of treating pulmonary arterial hypertension
WO2022238375A1 (en)	2021-05-11	2022-11-17	Actelion Pharmaceuticals Ltd	Methods of treating pulmonary hypertension
TW202317119A (zh) *	2021-06-11	2023-05-01	瑞士商艾克泰聯製藥有限公司	用於口服投予之分散錠
JP2024530727A (ja)	2021-08-25	2024-08-23	ビーエーエスエフソシエタス・ヨーロピア	直接打錠補助組成物
WO2023038600A1 (en) *	2021-09-07	2023-03-16	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A capsule formulation comprising macitentan
EP4154873A1 (en)	2021-09-22	2023-03-29	Sanovel Ilac Sanayi Ve Ticaret A.S.	The tablet comprising macitentan

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945098A (en)	1990-02-01	1999-08-31	Baxter International Inc.	Stable intravenously-administrable immune globulin preparation
JPH04103525A (ja)	1990-08-22	1992-04-06	Sanwa Kagaku Kenkyusho Co Ltd	難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) *	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
NZ256921A (en)	1992-10-02	1996-05-28	Pharmacia Ab	Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
US5811120A (en)	1994-03-02	1998-09-22	Eli Lilly And Company	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW442301B (en)	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
RU2172735C2 (ru)	1995-12-20	2001-08-27	Яманоути Фармасьютикал Ко., Лтд.	Арилэтенсульфонамидные производные и фармацевтическая композиция
JPH103525A (ja)	1996-06-14	1998-01-06	Dainippon Printing Co Ltd	Ｉｃカード、命令コード格納方法及び命令コード実行方法
AR017426A1 (es)	1997-12-08	2001-09-05	Smithkline Beecham Corp	Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
ATE219658T1 (de)	1998-03-06	2002-07-15	Eurand Int	Schnell zerfallende tablette
US20010014352A1 (en) *	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
US20040062803A1 (en) *	1999-12-22	2004-04-01	Hedden David B.	Sustained-release formulation of a cyclooxygenase-2 inhibitor
CZ20022293A3 (cs) *	1999-12-31	2003-04-16	Texas Biotechnology Corporation	Sulfonamidy a jejich deriváty, které upravují aktivitu endothelinu
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
JP2001335469A (ja)	2000-05-26	2001-12-04	Lion Corp	固体製剤の製造方法
KR20080064908A (ko)	2000-06-28	2008-07-09	테바 파마슈티컬 인더스트리즈 리미티드	카르베딜올
AU2256702A (en)	2000-12-01	2002-06-11	Kyowa Hakko Kogyo Kk	Composition improved in solubility or oral absorbability
AU3950802A (en)	2000-12-07	2002-06-18	Cv Therapeutics Inc	Abca-1 elevating compounds
BRPI0116237B8 (pt) *	2000-12-18	2021-05-25	Actelion Pharmaceuticals Ltd	"composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
FR2819720B1 (fr) *	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
JP3930290B2 (ja)	2001-09-12	2007-06-13	富士フイルム株式会社	熱現像感光材料及びそれを用いた熱現像方法
KR20030041577A (ko)	2001-11-20	2003-05-27	디디에스텍주식회사	난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
AU2003207461A1 (en) *	2002-01-07	2003-07-24	Pharmacia Corporation	Drug mixture with enhanced dissolution rate
JP4583761B2 (ja)	2002-02-11	2010-11-17	ファイザー・インク	Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体
JP4544863B2 (ja)	2002-02-26	2010-09-15	アストラゼネカアクチボラグ	水溶性セルロース誘導体を含むイレッサの医薬製剤
GB0204771D0 (en)	2002-02-28	2002-04-17	Phoqus Ltd	Fast disintegrating tablets
WO2004067008A1 (ja)	2003-01-28	2004-08-12	Takeda Pharmaceutical Company Limited	受容体作動薬
EP1601356A1 (en)	2003-02-25	2005-12-07	Eli Lilly and Company	Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
US7220738B2 (en)	2003-12-10	2007-05-22	Activbiotics, Inc.	Rifamycin analogs and uses thereof
US7094081B1 (en) *	2005-03-24	2006-08-22	Delphi Technologies, Inc.	Electrical connector assembly
PT1928409E (pt)	2005-09-12	2012-11-27	Actelion Pharmaceuticals Ltd	Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
WO2009104149A1 (en)	2008-02-20	2009-08-27	Actelion Pharmaceuticals Ltd	Combination comprising paclitaxel for treating ovarian cancer
PT2315587T (pt)	2008-08-13	2018-01-31	Actelion Pharmaceuticals Ltd	Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BR112013019680A2 (pt)	2011-02-04	2016-10-11	Actelion Pharmaceuticals Ltd	combinações compreendendo macitentana para o tratamento de glioblastoma multiforme

2006
- 2006-09-11 PT PT06809280T patent/PT1928409E/pt unknown
- 2006-09-11 BR BRPI0615898A patent/BRPI0615898B8/pt active IP Right Grant
- 2006-09-11 MY MYPI20080524 patent/MY151003A/en unknown
- 2006-09-11 AU AU2006290309A patent/AU2006290309B2/en active Active
- 2006-09-11 SI SI200631471T patent/SI1928409T1/sl unknown
- 2006-09-11 NZ NZ567188A patent/NZ567188A/en unknown
- 2006-09-11 RU RU2008113869/15A patent/RU2424805C2/ru active
- 2006-09-11 KR KR1020087008450A patent/KR101313395B1/ko active IP Right Review Request
- 2006-09-11 ES ES06809280T patent/ES2393117T3/es active Active
- 2006-09-11 PL PL06809280T patent/PL1928409T3/pl unknown
- 2006-09-11 DK DK06809280.8T patent/DK1928409T3/da active
- 2006-09-11 CA CA2621273A patent/CA2621273C/en active Active
- 2006-09-11 JP JP2008529767A patent/JP4955685B2/ja active Active
- 2006-09-11 WO PCT/IB2006/053210 patent/WO2007031933A2/en active Application Filing
- 2006-09-11 EP EP06809280A patent/EP1928409B1/en active Active
- 2006-09-11 US US12/066,448 patent/US20080233188A1/en not_active Abandoned
- 2006-09-11 CN CN2006800333751A patent/CN101262847B/zh active Active
- 2006-09-11 EP EP10009910A patent/EP2292209A3/en not_active Withdrawn
- 2006-09-12 TW TW095133695A patent/TWI323661B/zh active
2008
- 2008-03-11 IL IL190072A patent/IL190072A/en active IP Right Grant
- 2008-04-03 ZA ZA200802947A patent/ZA200802947B/xx unknown
- 2008-04-09 NO NO20081724A patent/NO341325B1/no unknown
2009
- 2009-02-18 US US12/388,142 patent/US8367685B2/en active Active
- 2009-03-09 HK HK09102261.9A patent/HK1121950A1/xx not_active IP Right Cessation
- 2009-05-01 JP JP2009112258A patent/JP5054061B2/ja active Active
2012
- 2012-11-21 CY CY20121101126T patent/CY1113395T1/el unknown
- 2012-11-23 HR HRP20120957TT patent/HRP20120957T1/hr unknown
2013
- 2013-01-08 US US13/736,699 patent/US9265762B2/en active Active
2016
- 2016-01-20 US US15/002,255 patent/US10117870B2/en active Active
2018
- 2018-02-20 US US15/900,586 patent/US10946015B2/en active Active
2020
- 2020-12-09 US US17/116,983 patent/US11648249B2/en active Active

Also Published As

Publication number	Publication date
JP2009519893A (ja)	2009-05-21
BRPI0615898B1 (pt)	2020-02-18
NO341325B1 (no)	2017-10-16
US10946015B2 (en)	2021-03-16
US20180263980A1 (en)	2018-09-20
TWI323661B (en)	2010-04-21
PT1928409E (pt)	2012-11-27
WO2007031933A3 (en)	2007-10-18
TW200803860A (en)	2008-01-16
AU2006290309B2 (en)	2012-04-05
US20160136163A1 (en)	2016-05-19
US11648249B2 (en)	2023-05-16
CN101262847A (zh)	2008-09-10
BRPI0615898B8 (pt)	2021-05-25
CN101262847B (zh)	2010-11-24
JP5054061B2 (ja)	2012-10-24
EP1928409B1 (en)	2012-09-12
JP2009235073A (ja)	2009-10-15
BRPI0615898A2 (pt)	2011-05-31
ES2393117T3 (es)	2012-12-18
KR101313395B1 (ko)	2013-10-02
WO2007031933A2 (en)	2007-03-22
CA2621273A1 (en)	2007-03-22
DK1928409T3 (da)	2012-11-05
AU2006290309A1 (en)	2007-03-22
US20210186966A1 (en)	2021-06-24
US9265762B2 (en)	2016-02-23
JP4955685B2 (ja)	2012-06-20
US8367685B2 (en)	2013-02-05
PL1928409T3 (pl)	2013-02-28
KR20080055897A (ko)	2008-06-19
EP2292209A2 (en)	2011-03-09
NZ567188A (en)	2011-04-29
IL190072A0 (en)	2008-08-07
NO20081724L (no)	2008-04-09
EP2292209A3 (en)	2011-05-04
IL190072A (en)	2013-08-29
RU2424805C2 (ru)	2011-07-27
EP1928409A2 (en)	2008-06-11
CA2621273C (en)	2014-07-29
US20130190336A1 (en)	2013-07-25
US20100004274A1 (en)	2010-01-07
HK1121950A1 (en)	2009-05-08
MY151003A (en)	2014-03-31
SI1928409T1 (sl)	2012-12-31
US20080233188A1 (en)	2008-09-25
HRP20120957T1 (hr)	2012-12-31
US10117870B2 (en)	2018-11-06
CY1113395T1 (el)	2016-06-22
RU2008113869A (ru)	2009-10-20

Publication	Publication Date	Title
HK1121950A1 (en)	2009-05-08	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
HK1244267A1 (zh)	2018-08-03	包含(r)-n-甲基納曲酮的藥物組合物
ZA200606229B (en)	2009-12-30	A pharmaceutical composition
IL177480A0 (en)	2006-12-10	Pharmaceutical composition
IL186336A0 (en)	2008-01-20	Pharmaceutical composition
IL188352A0 (en)	2008-04-13	Pharmaceutical compositions
IL187748A0 (en)	2008-04-13	Pharmaceutical compositions containing misoprostal
ZA200804103B (en)	2009-10-28	Pharmaceutical compositions
IL182703A0 (en)	2007-09-20	Pharmaceutical compositions comprising a camtothecin derivative
EP1937255A4 (en)	2013-06-26	PHARMACEUTICAL COMPOSITION
EP1862184A4 (en)	2012-12-19	PHARMACEUTICAL COMPOSITION
IL184631A0 (en)	2009-09-22	PHARMACEUTICAL COMPOSITIONS CONTAINING A Wht3a PROTEIN
IL192091A0 (en)	2008-12-29	Pharmaceutical compositions
HU0401177D0 (en)	2004-08-30	Pharmaceutical composition
GB2411355B (en)	2006-02-22	Pharmaceutical composition
GB0400452D0 (en)	2004-02-11	A pharmaceutical composition
ZA200701932B (en)	2008-08-27	Pharmaceutical composition
GB0425255D0 (en)	2004-12-15	Pharmaceutical composition
EP1845944A4 (en)	2011-07-27	PHARMACEUTICAL COMPOSITIONS
GB0522045D0 (en)	2005-12-07	Pharmaceutical compositions
ZA200701931B (en)	2008-10-29	Pharmaceutical composition
ZA200803566B (en)	2009-10-28	Pharmaceutical compositions
EP1864664A4 (en)	2009-02-18	PHARMACEUTICAL PREPARATION
GB0512246D0 (en)	2005-07-27	Novel pharmaceutical
GB0522473D0 (en)	2005-12-14	A pharmaceutical formulation